DUBAI, UAE, Jan. 20, 2026 /PRNewswire/ — Mantle, the high-performance distribution and liquidity layer bridging traditional finance (TradFi), real-world assets (RWAs) and on-chain liquidity, today announced a new collaboration with Everclear, introducing Cross-Chain Asset Settlement to the Mantle ecosystem that allows users to seamlessly swap wETH from Ethereum, Arbitrum, Base, or Polygon directly into mETH on Mantle — without traditional bridging friction.

This integration addresses one of the most pressing challenges in multi-chain DeFi: liquidity fragmentation across multiple representations of the same asset.

Solving Fragmentation with Cross-Chain Netting & Settlement

As ecosystems scale, assets like ETH and USD now exist in many forms, from wETH, mETH, stETH to an expanding set of stablecoins. Everclear’s clearing and settlement infrastructure solves this fragmentation by netting cross-chain flows and automatically rebalancing inventory, reducing redundant liquidity and lowering costs.

With this launch, users can access Mantle directly using assets they already hold, while Everclear handles settlement and rebalancing behind the scenes.

“Real-world usability of on-chain assets depends on efficient settlement across chains,” said Emily Bao, Key Advisor of Mantle. “This integration reinforces Mantle’s RWA and ETH-native strategy by removing onboarding friction and enabling capital to flow into the ecosystem in a more scalable, institutional-grade way.”

How It Works: wETH → mETH in Under One Minute

Users holding wETH on supported chains can select Mantle as the destination and receive mETH on Mantle in a single transaction, typically in under one minute.

Everclear’s solver infrastructure fills user intents immediately, while netting and rebalancing cross-chain flows in the background to restore inventory at the lowest possible cost — delivering better pricing, no slippage, and fast execution.

“Everclear was built to be the settlement layer for a fragmented, multi-asset future,” said Nikita Bulgakov from Everclear Foundation. “By connecting different representations of the same asset, we enable partners like Mantle and mETH Protocol to offer a truly chain-abstracted experience to users.”

Unlocking Capital-Efficient Access to Mantle’s Ecosystem

Starting with mETH, this collaboration allows users to enter Mantle’s ecosystem without manually bridging or swapping assets, a key barrier for both retail and advanced users.

Key benefits include:

• Seamless onboarding into Mantle from major Ethereum ecosystems
• Improved liquidity efficiency through netting and clearing
• Faster settlement with capital-efficient execution
• A foundation for expanding to more ETH-based and stable assets

A Foundation for Chain-Abstracted Finance

Mantle is the first launch partner for Everclear’s expanded cross-asset settlement initiative, with future plans to support additional ETH-based assets, stablecoins, and new chains.

This collaboration reflects a broader industry shift toward chain-abstracted finance, where users interact with assets and applications without needing to manage the complexity of bridges, liquidity pools, or fragmented representations.

About Mantle

Mantle positions itself as the premier distribution layer and gateway for institutions and TradFi to connect with on-chain liquidity and access real-world assets, powering how real-world finance flows.

With over $4B+ in community-owned assets, Mantle combines credibility, liquidity and scalability with institutional-grade infrastructure to support large-scale adoption. The ecosystem is anchored by $MNT within Bybit, and built out through core ecosystem projects like mETH, fBTC, MI4 and more. This is complemented by Mantle Network’s partnerships with leading issuers and protocols such as Ethena USDe, Ondo USDY, and OP-Succinct.

For more information about Mantle, please visit: mantle.xyz
For more social updates, please follow: Mantle Official X & Mantle Community Channel 
For media enquiries, please contact: contact@mantle.xyz

About Everclear

Everclear (formerly Connext) is an interoperability protocol focused on crosschain settlement and liquidity rebalancing for professional users, including market makers, solvers, bridges, and exchanges. Operating as a highly efficient B2B clearing and settlement layer, Everclear powers leading partners such as Across, Relay, LI.FI, Eco, and others, processing approximately $400M in monthly volume across blue-chip assets and stablecoins.

Everclear recently launched Crosschain Asset Settlement and offers custom interoperability solutions, including white-label crosschain deposits, staking, and tailored flows—enabling partners to efficiently attract users and liquidity from long-tail chains.

About mETH Protocol

mETH Protocol is a vertically integrated liquid staking and restaking protocol incubated by Mantle, operating at the intersection of DeFi composability and institutional-grade ETH yield access. With a peak total value locked (TVL) of $2.19 billion achieved within its first year, mETH Protocol is supported by leading validator and custody partners, including P2P, Kraken Staked, OSL, and Copper. The protocol is embedded across over 40+ leading DeFi and exchange platforms such as Bybit, Ethena, and more, whilst incorporated in treasury frameworks for DAOs and corporates as a core liquidity and yield layer.

All-Cash Structure Increases Value Certainty for WBD Stockholders, Accelerates WBD Stockholder Vote and Underscores Netflix’s Financial Strength

WBD Files Preliminary Proxy Statement for Transaction Approval

HOLLYWOOD, Calif. and NEW YORK, Jan. 20, 2026 /PRNewswire/ — Netflix, Inc. (NASDAQ:NFLX) (“Netflix”) and Warner Bros. Discovery, Inc. (“WBD” or “Warner Bros. Discovery”) announced they have amended their definitive agreement for Netflix’s pending acquisition of Warner Bros. to an all-cash transaction. The revised agreement simplifies the transaction structure, provides greater certainty of value for WBD stockholders, and accelerates the path to a WBD stockholder vote.

The all-cash transaction continues to be valued at $27.75 per WBD share, unchanged from the prior transaction structure. WBD stockholders will also receive the additional value of shares of Discovery Global following its separation from WBD. The transaction will be financed through a combination of cash on hand, available credit facilities and committed financing.

The revised structure enhances execution certainty, aligns with Netflix’s disciplined capital allocation framework and provides clear benefits, including:

• Greater Value Certainty: The all-cash transaction provides enhanced certainty around the value WBD stockholders will receive at closing, eliminating market-based variability.
• Faster Path to Stockholder Vote: The revised transaction structure is expected to enable WBD stockholders to vote on the proposed transaction by April 2026. To support this accelerated timeline, WBD has today filed its preliminary proxy statement with the SEC. 

Netflix’s strong cash flow generation supports the revised all-cash transaction structure while preserving a healthy balance sheet and flexibility to capitalize on future strategic priorities.

“Today’s revised merger agreement brings us even closer to combining two of the greatest storytelling companies in the world and with it even more people enjoying the entertainment they love to watch the most,” said David Zaslav, President and CEO of Warner Bros. Discovery. “By coming together with Netflix, we will combine the stories Warner Bros. has told that have captured the world’s attention for more than a century and ensure audiences continue to enjoy them for generations to come.”

“The WBD Board continues to support and unanimously recommend our transaction, and we are confident that it will deliver the best outcome for stockholders, consumers, creators and the broader entertainment community,” said Ted Sarandos, co-CEO of Netflix. “Our revised all-cash agreement will enable an expedited timeline to a stockholder vote and provide greater financial certainty at $27.75 per share in cash, plus the value from the planned separation of Discovery Global. Together, Netflix and Warner Bros. will deliver broader choice and greater value to audiences worldwide, enhancing access to world-class television and film both at home and in theaters. The acquisition will also significantly expand U.S. production capacity and investment in original programming, driving job creation and long-term industry growth.”  

“Over the last decade, when much of the entertainment industry has contracted, Netflix has grown and invested tremendously in the business of film and television in the U.S. and abroad. This transaction will further fuel that growth and investment,” said Greg Peters, co-CEO of Netflix. “By amending our agreement today, we are underscoring what we have believed all along: not only does our transaction provide superior stockholder value, it is also fundamentally pro-consumer, pro-innovation, pro-creator and pro-growth. Our revised all-cash agreement demonstrates our commitment to the transaction with Warner Bros. and provides WBD stockholders with an accelerated process and the financial certainty of cash consideration, while maintaining our commitment to a healthy balance sheet and our solid investment grade ratings. We will continue to work closely with WBD to successfully complete the transaction as we remain focused on our mission to entertain the world and, together, define the next century of storytelling.”

“Our amended agreement with Netflix is a testament to the Board’s unrelenting focus on representing and advancing our stockholders’ interests,” said Samuel A. Di Piazza, Jr., Chair of the Warner Bros. Discovery Board of Directors. “By transitioning to  all-cash consideration, we can now deliver the incredible value of our combination with Netflix at even greater levels of certainty, while providing our stockholders  the opportunity to participate in management’s strategic plans to realize the value of Discovery Global’s iconic brands and global reach. We look forward to continuing to engage with our investors about the compelling benefits of the transaction as we progress toward our stockholder  vote on an accelerated timeline.”

As previously announced, WBD will separate Warner Bros. and Discovery Global into two separate publicly traded companies. This separation is expected to be completed in six to nine months, prior to the closing of the proposed Netflix and Warner Bros. transaction. 

The amended, all-cash transaction was unanimously approved by the Boards of Directors of both Netflix and WBD. Closing remains subject to completion of the Discovery Global separation, receipt of required regulatory approvals, approval of WBD stockholders and other customary closing conditions. The financing structure is not subject to review by the Committee on Foreign Investment in the United States (CFIUS). 

Netflix and WBD have each submitted their Hart-Scott-Rodino (HSR) filings and are engaging with competition authorities, including the U.S. Department of Justice and European Commission. Netflix and WBD remain committed to working closely with regulators and all stakeholders to ensure a smooth and successful transaction. As previously disclosed, the transaction is expected to close 12-18 months from the date that Netflix and WBD originally entered into their merger agreement.

Advisors
Moelis & Company LLC is acting as Netflix’s financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal counsel. Wells Fargo is acting as an additional financial advisor and, along with BNP and HSBC, are serving as lead arrangers for the debt financing related to the transaction.

Allen & Company, J.P. Morgan and Evercore are serving as financial advisors to Warner Bros. Discovery and Wachtell, Lipton, Rosen & Katz and Debevoise & Plimpton LLP are serving as legal counsel.

A dedicated website providing ongoing information and resources about the transaction is available at netflixwbtogether.com. 

About Netflix, Inc.
Netflix is one of the world’s leading entertainment services offering TV series, films, games and live programming across a wide variety of genres and languages. Members can play, pause and resume watching as much as they want, anytime, anywhere, and can change their plans at any time.

About Warner Bros. Discovery
Warner Bros. Discovery is a leading global media and entertainment company that creates and distributes the world’s most differentiated and complete portfolio of branded content across television, film, streaming and gaming. Warner Bros. Discovery inspires, informs and entertains audiences worldwide through its iconic brands and products including: Discovery Channel, HBO Max, discovery+, CNN, DC, TNT Sports, Eurosport, HBO, HGTV, Food Network, OWN, Investigation Discovery, TLC, Magnolia Network, TNT, TBS, truTV, Travel Channel, Animal Planet, Science Channel, Warner Bros. Motion Picture Group, Warner Bros. Television Group, Warner Bros. Pictures Animation, Warner Bros. Games, New Line Cinema, Cartoon Network, Adult Swim, Turner Classic Movies, Discovery en Español, Hogar de HGTV and others. For more information, please visit www.wbd.com.

Important Information About the Transaction and Where to Find It

This communication may be deemed to be solicitation material in respect of the proposed transaction between WBD and Netflix (the “proposed transaction”). In connection with the proposed transaction between Netflix and WBD, WBD filed a preliminary proxy statement on Schedule 14A (the “Proxy Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) on January 20, 2026. The preliminary Proxy Statement is not final and may be amended, and the definitive Proxy Statement (if and when available) will be mailed to stockholders of WBD.  WBD also intends to file a registration statement for the newly formed subsidiary of WBD (“Discovery Global”) that will be spun off from WBD prior to the closing of the proposed transaction. Each of Netflix and WBD may also file with or furnish to the SEC other relevant documents regarding the proposed transaction. This communication is not a substitute for the Proxy Statement or any other document that Netflix or WBD may file with the SEC or mail to WBD’s stockholders in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF NETFLIX AND WBD ARE URGED TO READ THE PROXY STATEMENT, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE INTO THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION REGARDING NETFLIX, WBD, THE PROPOSED TRANSACTION AND RELATED MATTERS. The documents filed by Netflix with the SEC also may be obtained free of charge at Netflix’s website at https://ir.netflix.net/home/default.aspx. The documents filed by WBD with the SEC also may be obtained free of charge at WBD’s website at https://ir.wbd.com.

Participants in the Solicitation

Netflix, WBD and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of WBD in connection with the proposed transaction under the rules of the SEC. Information about the interests of the directors and executive officers of WBD and other persons who may be deemed to be participants in the solicitation of stockholders of WBD in connection with the proposed transaction and a description of their direct and indirect interests, by security holdings or otherwise, will be included in the Proxy Statement, which will be filed by WBD with the SEC. Information about WBD’s directors and executive officers is set forth in WBD’s proxy statement for its 2025 Annual Meeting of Stockholders on Schedule 14A filed with the SEC on April 23, 2025, WBD’s Annual Report on Form 10-K for the year ended December 31, 2024, and any subsequent filings with the SEC. Information about Netflix’s directors and executive officers is set forth in Netflix’s proxy statement for its 2025 Annual Meeting of Stockholders on Schedule 14A filed with the SEC on April 17, 2025, and any subsequent filings with the SEC. Additional information regarding the direct and indirect interests of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the Proxy Statement regarding the proposed transaction when it becomes available. Free copies of these documents may be obtained as described above.

Cautionary Statement Regarding Forward-Looking Statements

This document contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on Netflix’s and WBD’s current expectations, estimates and projections about the expected date of closing of the proposed transaction and the potential benefits thereof, their respective businesses and industries, management’s beliefs and certain assumptions made by Netflix and WBD, all of which are subject to change. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “could,” “seek,” “see,” “will,” “may,” “would,” “might,” “potentially,” “estimate,” “continue,” “expect,” “target,” similar expressions or the negatives of these words or other comparable terminology that convey uncertainty of future events or outcomes. All forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond our control and are not guarantees of future results, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. These and other forward-looking statements, including the failure to consummate the proposed transaction or to make or take any filing or other action required to consummate the transaction on a timely matter or at all, are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements and caution must be exercised in relying on forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to: (i) the completion of the proposed transaction on anticipated terms and timing, including obtaining stockholder and regulatory approvals, completing the separation of WBD’s Discovery Global business and Warner Bros. business, anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies, expansion and growth of WBD’s and Netflix’s businesses and other conditions to the completion of the proposed transaction; (ii) failure to realize the anticipated benefits of the proposed transaction, including as a result of delay in completing the transaction or integrating the businesses of Netflix and WBD; (iii) Netflix’s and WBD’s ability to implement their business strategies; (iv) consumer viewing trends; (v) potential litigation relating to the proposed transaction that could be instituted against Netflix, WBD or their respective directors; (vi) the risk that disruptions from the proposed transaction will harm Netflix’s or WBD’s business, including current plans and operations; (vii) the ability of Netflix or WBD to retain and hire key personnel; (viii) potential adverse reactions or changes to business relationships resulting from the announcement, pendency or completion of the proposed transaction; (ix) uncertainty as to the long-term value of Netflix’s common stock; (x) legislative, regulatory and economic developments affecting Netflix’s and WBD’s businesses; (xi) general economic and market developments and conditions; (xii) the evolving legal, regulatory and tax regimes under which Netflix and WBD operate; (xiii) potential business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction that could affect Netflix’s or WBD’s financial performance; (xiv) restrictions during the pendency of the proposed transaction that may impact Netflix’s or WBD’s ability to pursue certain business opportunities or strategic transactions; and (xv) failure to receive the approval of the stockholders of WBD. Discussions of additional risks and uncertainties are contained in Netflix’s and WBD’s filings with the SEC, including their Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, and the Proxy Statement filed by WBD in connection with the proposed transaction and the registration statement to be filed by Discovery Global in connection with the separation.  While the list of factors presented here is, and the list of factors presented in the Proxy Statement and registration statement will be, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Netflix’s or WBD’s consolidated financial condition, results of operations or liquidity. Neither Netflix nor WBD assumes any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

BEIJING, Jan. 20, 2026 /PRNewswire/ — Galbot, a global pioneer in embodied AI and general-purpose robotics, announced the launch of the Galbot S1, an industrial-grade heavy-duty embodied intelligence robot designed to meet the growing demands of modern manufacturing. This breaks the long-standing payload limit in the industry, achieving a continuous dual-arm payload of 50kg. This breakthrough robot pushes the industry’s payload limits, achieving a continuous dual-arm payload of up to 50kg. The Galbot S1 has already been successfully deployed in the core production lines of manufacturing giants such as CATL, marking a historic shift for embodied AI from experimental demonstrations to real-world industrial applications.

A New Era for Manufacturing: Galbot S1 Meets Real-World Heavy-Duty Needs

The manufacturing sector is facing unprecedented challenges. From heavy, long-duration tasks to dynamic environments with varying conditions, the demand for advanced, adaptable solutions has never been greater. The Galbot S1 is designed to meet these challenges, seamlessly integrating into production lines and providing a reliable, high-capacity solution.

Unlike traditional industrial robots that often rely on pre-programmed tasks or teleoperation, the Galbot S1 is purpose-built for the intense, continuous operations required in real-world industrial settings. It operates reliably in environments where dust, vibration, lighting changes, and human interaction are a part of the daily workflow.

Breaking Load Limits: A True Industry Game-Changer with 50KG Payload

The Galbot S1 represents a major breakthrough in embodied intelligence for the industrial sector. It can handle a dual-arm load of up to 50kg, offering unprecedented flexibility to meet the ever-changing needs of the manufacturing process. Operating autonomously without the need for teleoperation, the robot adapts to dynamic environments with advanced real-time responses and 360° omnidirectional obstacle avoidance. Its intelligent system ensures safety while maintaining high operational efficiency, even in challenging conditions.

Designed for Long-Term, Seamless Operations

Engineered for extended use, the Galbot S1 offers up to 8 hours of continuous operation on a single charge. Equipped with a dual-battery quick-swap design, it can autonomously replace its batteries, ensuring 24/7 operation in demanding industrial environments. This design ensures the Galbot S1 can keep up with the fast-paced requirements of modern production lines.

Powered by Galbot’s proprietary AI, the robot’s embodied handling model allows it to perform complex material handling tasks with high precision. The robot operates purely based on visual perception, eliminating the need for QR codes or labels for positioning. This means the Galbot S1 integrates seamlessly into existing production environments with minimal recalibration. It marks a significant step towards mass adoption of embodied intelligence in industrial production.

From Lab to Real-World Deployment: Validation at CATL

The ultimate validation of the Galbot S1 comes from its real-world deployment. It is currently in operation at CATL, the world’s leading battery manufacturer, handling critical heavy-load tasks on the production line. This deployment validates the Galbot S1’s ability to meet the stringent rhythm and stability requirements of advanced manufacturing. Beyond CATL, Galbot has forged partnerships with leading global manufacturers such as Bosch Group, Toyota, BAIC Group, SAIC Group, and Zeekr to explore new paradigms in flexible manufacturing powered by embodied AI.

As Galbot continues to expand its footprint in key industrial sectors, the Galbot S1 will play a pivotal role in shaping the future of manufacturing, transforming how industries approach automation and productivity. By focusing on real-world applications and scalability, Galbot is positioning itself as a leader in the evolution of embodied intelligence in the industrial sector.

About Galbot

Beijing Galbot AI Co., Ltd. is a global pioneer in embodied AI and general-purpose robotics. With R&D centers in Beijing, Shenzhen, Suzhou, and Hong Kong, Galbot brings together world-class scientists and engineers with decades of experience in embodied intelligence and robotics. Its flagship product, the Galbot G1, has been widely deployed in industrial, logistics, retail, healthcare, and education, achieving over one year of proven and stable real-world operations.

As an industry leader, Galbot is driving continuous innovation in embodied AI and accelerating the global deployment of autonomous, general-purpose humanoid robots.

Patent-pending direct-on-vial RFID label enables DSCSA-ready traceability across pharmaceutical manufacturing and hospital workflows

TAICHUNG, Jan. 20, 2026 /PRNewswire/ — SAG today announced LiquidMate O, its debut UHF RFID label and a category-defining advancement in pharmaceutical RFID and item-level traceability. Built on an innovative, patent-pending antenna architecture, LiquidMate O delivers reliable direct-on-vial RFID tagging for liquid-filled injectable medications, an application long considered one of the most technically challenging in RFID deployment. Ineffective tracking of injectable drugs continues to drive substantial losses through expired inventory, misplaced medications, and regulatory exposure—particularly for high-value or critical products. As enforcement of the U.S. Drug Supply Chain Security Act (DSCSA) accelerates, dependable, high-accuracy RFID-based medication tracking has become essential to both pharmaceutical manufacturing and hospital operations.

LiquidMate O is purpose-built to enable scalable, item-level tracking across a broad range of injectable liquid categories that have historically constrained direct-on-vial RFID adoption. Its performance has been independently validated through AXIA Lab–defined test scenarios, using representative liquid formulations and workflow conditions aligned with real clinical practice. Key capabilities include:

• One label across multiple formulations
  Consistent RFID performance across injectable liquids with varying dielectric properties, eliminating formulation-specific labels and significantly reducing SKU complexity.
• True direct-on-vial design
  Validated on industry-standard 10 mL glass vials with a compact 62 × 20 mm label engineered for curved, space-constrained pharmaceutical packaging.
• Proven high-density readability
  Independently validated by AXIA Lab, achieving 100% read performance in dense, multi-vial configurations with full 360-degree omnidirectional readability.

While demand for item-level traceability continues to rise, existing RFID approaches have struggled to balance RF performance, scalability, and operational integration. Conventional direct-on-vial solutions often suffer from inconsistent performance on liquid-filled injectables due to dielectric effects, while flag-style labels, although RF-robust, pose handling, automation, and scalability challenges that limit broader adoption. LiquidMate O eliminates this trade-off by delivering a true direct-on-vial RFID solution with consistent performance across diverse injectable formulations. This enables streamlined labeling operations and improved workflow efficiency from manufacturing through point-of-care. By reducing manual scanning steps and minimizing SKU proliferation, LiquidMate O supports real-time inventory visibility, accurate dispensing, and enhanced patient safety without disrupting existing packaging lines.

“With more than two decades of experience supporting healthcare and industrial RFID applications, we have seen how reliability at the item level directly impacts compliance, efficiency, and patient safety,” said Terry Chiang, CEO of SAG. “LiquidMate O reflects our focus on solving the most technically complex tagging challenges in healthcare and delivering scalable, standards-based traceability solutions that pharmaceutical organizations can deploy with confidence.”

Following extensive engineering development and independent validation, LiquidMate O is now qualified for commercial deployment. Built on SAG’s deep expertise in RFID antenna design, materials science, and healthcare workflow integration, the solution is engineered to meet the stringent performance, regulatory, and scalability requirements of pharmaceutical environments. SAG is initiating structured technical engagements to support evaluation and deployment planning for next-generation item-level traceability initiatives.

About SAG

As an RFID tagging challenge enabler, SAG turns complex concepts into production-ready RFID solutions. Through deep expertise in tailored antenna design, materials science, and self-developed manufacturing systems, SAG delivers reliable RFID connectivity that performs under demanding operational and environmental constraints—enabling organizations to address complex, mission-critical workflow challenges through advanced RFID solutions.

www.sag-rfid.com
info@sag.com.tw 

Grant Proceeds Will Accelerate Research Into Advanced Fiber-based Electronic Battery Systems

DALLAS, Jan. 20, 2026 /PRNewswire/ — Solidion Technology Inc. (“Solidion” or the “Company”) (Nasdaq: STI), an advanced battery technology solutions provider, was notified by the U.S. Department of War/Army STTR Program that it has been awarded a grant to develop an advanced fiber-based electronic battery system built on a coaxial carbon nanotube (CNT) yarn architecture. This marks the third grant Solidion has received in the last six months.

The Company previously announced that it had received the prestigious 2025 R&D 100 Award in partnership with Oak Ridge National Laboratory (ORNL), for innovation in Electrochemical Graphitization in Molten Salts (E-GRIMS) as well as a grant to advance research and development of Electrochemical Manufacturing of High-Performance Graphite Based on Biomass-Derived Carbon funded by ARPA-E, the Advanced Research Projects Agency, from their highly competitive OPEN program and to scale up the synthesis of a carbon-nanosphere material that will be used as an anti-corrosive additive in molten-salts-based heat transfer fluids for advanced molten salt nuclear reactors.

KEY HIGHLIGHTS OF SOLIDION’S THIRD GOVERNMENT GRANT

• Collaboration: Research to be conducted jointly with The University of Texas at Dallas
• Diversification: This innovation is a flexible, rechargeable lithium-ion battery in fiber form: a CNT yarn serves as both the structural core and current collector of the anode, integrated with Solidion’s silicon (Si) as the high-capacity anode material.

Jaymes Winters, Chief Executive Officer of Solidion Technology, stated:

“Advancements in advanced fiber based electronic battery systems are a part of the larger commitment by the Department of War to innovate and collaborate with cutting edge U.S. companies such as Solidion.”

About Solidion Technology, Inc.

Headquartered in Dallas, Texas with pilot production facilities in Dayton, Ohio, Solidion’s (NASDAQ: STI) core business includes manufacturing of battery materials and components, as well as development and production of next-generation batteries for energy storage systems, including including UPS systems serving the artificial intelligence (AI) data center market and electric vehicles for ground, aerospace, and sea transportation. Solidion holds a portfolio of over 525 patents, covering innovations such as high-capacity, silane gas free and graphene-enabled silicon anodes, biomass-based graphite, advanced lithium-sulfur and lithium-metal technologies.

For more information, please visit www.solidiontech.com or contact Investor Relations.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Solidion Technology Inc., (NASDAQ: STI) (the “Company,” “Solidion,” “we,” “our” or “us”) desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “forecasts” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by law.

Funding will scale hospital deployments for groundbreaking CT:VQ™ imaging product, strongly advance R&D, support early adopters at Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, and more

LOS ANGELES and MELBOURNE, Australia, Jan. 20, 2026 /PRNewswire/ — 4DMedical, the leader in software-based respiratory imaging technology, today announced US$100+ million (AU$150 million) in new institutional placement. The investment will primarily be leveraged to accelerate U.S. adoption of its class-leading “CT:VQ™” product and significantly boost research and development—bolstering 4D’s technology lead in software-based lung imaging.

Backed by new institutional funding, 4DMedical is advancing its respiratory imaging technology and expanding the U.S. rollout of its FDA-cleared CT:VQ™ software.

CT:VQ™ is 4DMedical’s FDA-cleared, SaaS technology that provides ventilation and perfusion insights from CT imaging. Within just four months of FDA clearance, CT:VQ was deployed by four elite U.S. academic medical centers: Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health. These rapid adoptions reflect growing interest from clinicians seeking quantified, actionable and functional information not available from traditional imaging–but increasingly vital to support diagnosis, treatment planning, and longitudinal monitoring.

“This is an extraordinarily important and validating event for multiple reasons,” says Andreas Fouras, PhD, 4DMedical Founder and CEO. “First, it reflects growing global recognition of the technological leadership of 4DMedical, including our groundbreaking products such as CT:VQ™. And it recognizes both the commercial progress and even greater growth potential we have in the U.S. With this strong institutional backing and a strengthened balance sheet, we will scale adoption, accelerate R&D, deepen partnerships, and dominate the global marketplace for software-based lung imaging tools.”

What the funding enables for hospitals and health systems

4DMedical will use the funding to expand U.S. availability of CT:VQ™ and support health systems with implementation at scale, including:

• Commercial expansion across U.S. academic medical centers and health systems, with a focus on real-world adoption and multidisciplinary use
• Customer success, training, and technical support to help integrate CT:VQ™ into existing clinical workflows and drive consistent utilization
• Ongoing research and development to expand 4DMedical’s technology leadership, product portfolio and capabilities in functional lung imaging
• Operational scale and flexibility to support additional growth opportunities and sustained clinical partnerships

Following the raise, 4DMedical reported a pro forma cash position exceeding US$130+ million (AU$200+ million), which will support the company’s U.S. expansion strategy and growing installed base.

Built to integrate into clinical workflows

4DMedical’s products are delivered through a Software-as-a-Service (SaaS) model designed to integrate with existing hospital infrastructure. The company also highlighted strategic partnerships, including with Philips, aimed at supporting broader adoption pathways.

Availability

Hospitals and imaging networks interested in evaluating CT:VQ™ can contact 4DMedical for implementation information, workflow considerations, and a demonstration.

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that creates and deploys the most advanced software-based cardiothoracic imaging technology—integrating both proprietary algorithms and artificial intelligence. 4DMedical’s software platform delivers deep, quantitative, insights from routine clinical imaging to help clinicians assess lung function and cardiopulmonary disease with significantly greater precision.

These insights help pulmonologists, radiologists and hospital teams quantify regional lung function, support diagnosis and disease monitoring, and inform treatment and surgical planning. 4DMedical’s solutions are designed to integrate into existing clinical workflows. They provide actionable, patient-specific information that supports better decision-making and operational efficiency across a range of respiratory conditions. Learn more at www.4dmedical.com.

Photo – https://laotiantimes.com/wp-content/uploads/2026/01/4dmedical_respiratory_imaging.jpg